Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Abu Sheriff

Clinical Nurse Specialist, Adult Health Woodbridge, VA Nurse Practitioner

NPI 1043764632 CMS profile 10426949

12731 Marblestone Dr Ste 200, Woodbridge, VA 22192

Open in the dashboard

General payments

$2,911

139 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abu Sheriff of Woodbridge, VA is reported in the CMS Open Payments database as having received $2,911 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $949 38
2024 General $954 46
2023 General $623 33
2022 General $162 9
2021 General $222 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abu Sheriff
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Abu Sheriff were reported at $949. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Abu Sheriff Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $222 $133 $48–$445 $132
2022 $162 $163 $57–$526 $149
2023 $623 $173 $64–$597 $160
2024 $954 $171 $54–$575 $164
2025 $949 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $832 40 payments
  2. Lilly USA, LLC $424 18 payments
  3. AstraZeneca Pharmaceuticals LP $384 19 payments
  4. AbbVie, Inc. $378 17 payments
  5. GlaxoSmithKline, LLC. $240 14 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $123 6 payments
  7. Merck Sharp & Dohme Corporation $77 4 payments
  8. Boston Scientific Corporation $74 2 payments
  9. Astellas Pharma US Inc $73 3 payments
  10. Mylan Specialty L.P. $59 3 payments
  11. Other $246 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,897 138 payments
  2. Entertainment $14 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $573 25 payments
  2. RYBELSUS $573 25 payments
  3. MOUNJARO $366 16 payments
  4. ZEPBOUND $310 12 payments
  5. UBRELVY $298 13 payments
  6. TRELEGY ELLIPTA $240 14 payments
  7. QULIPTA $179 7 payments
  8. AIRSUPRA $168 8 payments
  9. BREZTRI $164 9 payments
  10. Wegovy $156 9 payments
  11. Other $1,214 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

1,446

Median for Nurse Practitioner: 389

Drug cost

$61,134

Median for Nurse Practitioner: $21,885

Branded share of claims

17.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 28 $26,075
Eliquis Apixaban Brand 12 $17,034
Symbicort Budesonide/Formoterol Fumarate Brand 11 $7,218
Albuterol Sulfate Hfa Albuterol Sulfate Brand 47 $919
Atorvastatin Calcium Generic 67 $784
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $782
Levothyroxine Sodium Generic 76 $683
Rosuvastatin Calcium Generic 68 $571
Ondansetron Odt Ondansetron Brand 16 $423
Losartan Potassium Generic 60 $396

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$35,108

Medicare's payments for the services billed

Medicare patients

239

Average age 72

Services billed

813

155 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 42%
Diabetes 31%
Chronic kidney disease 21%
Ischemic heart disease 20%
Depression 18%
Atrial fibrillation 15%
Heart failure 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $127
$127 — —
RYBELSUS
  • Novo Nordisk Inc $100
$100 — —
Ozempic
  • Novo Nordisk Inc $100
$100 28 —
Wegovy
  • Novo Nordisk Inc $69
$69 — —
QULIPTA
  • AbbVie, Inc. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record